Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
BIOVICA INTERNATIONAL AB (P..215.25%119
EXACT SCIENCES CORPORATION11.72%15 515
GUARDANT HEALTH, INC.31.48%10 061
BGI GENOMICS CO., LTD.110.33%8 876
-
ADAPTIVE BIOTECHNOLOGIES CO..66.11%7 019
SEEGENE INC--.--%6 461
INVITAE CORPORATION200.00%6 198
IOVANCE BIOTHERAPEUTICS, IN..31.36%5 512
-
CAREDX, INC137.92%2 525
VERACYTE, INC.48.85%2 423
Q-LINEA AB (PUBL)160.87%451
EPIGENOMICS AG-43.00%127
BIOVICA INTERNATIONAL AB (P..213.56%119
More Results
Financials
Sales 2021 19,5 M 2,21 M 2,21 M
Net income 2021 -32,5 M -3,68 M -3,68 M
Net cash 2021 6,50 M 0,74 M 0,74 M
P/E ratio 2021 -26,7x
Yield 2021 -
Capitalization 1 046 M 119 M 119 M
EV / Sales 2021 53,3x
EV / Sales 2022 23,4x
Nbr of Employees 21
Free-Float 70,3%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision